Company Description
PAVmed Inc. operates as a medical device company in the United States.
The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay.
Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring.
The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015.
PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| IPO Date | Jul 27, 2016 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Dr. Lishan Aklog M.D. |
Contact Details
Address: One Grand Central Place New York, New York United States | |
| Website | https://www.pavmed.com |
Stock Details
| Ticker Symbol | PAVM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001624326 |
| CUSIP Number | 70387R106 |
| ISIN Number | US70387R4039 |
| Employer ID | 47-1214177 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman & Chief Executive Officer |
| Dennis M. McGrath CPA | President & Chief Financial Officer |
| Shaun M. O'Neill M.B.A. | Executive Vice President & Chief Operating Officer |
| Dr. Brian J. deGuzman M.D. | Executive Vice President, Chief Technology & Compliance Officer |
| Dr. Deepika A. Lakhani Ph.D. | Senior Vice President, Chief Regulatory & Quality Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Senior Vice President of Molecular Genetics & Chief Scientific Officer |
| Dr. Victoria T. Lee M.D. | Senior Vice President & Chief Medical Officer |
| Michael Parks | Vice President of Investor Relations |
| Michael Adam Gordon | Executive Vice President, General Counsel & Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | SC 13D/A | [Amend] Filing |
| Dec 06, 2024 | DEF 14A | Filing |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 21, 2024 | PRE 14A | Filing |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Oct 23, 2024 | 4 | Filing |
| Sep 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |